Patents Assigned to Merck
-
Publication number: 20250152658Abstract: Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, wherein X1, X2, X3, R1-R9, RA, RB, RD, A1, A2, and subscripts t and w are as herein described. The compounds and their pharmaceutically acceptable salts can trap IL-1? and are expected to have utility as therapeutic agents, for example, for treating cardiovascular disease and inflammatory disorders. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cardiovascular disease and inflammatory disorders and for preparing pharmaceuticals for this purpose.Type: ApplicationFiled: November 12, 2024Publication date: May 15, 2025Applicant: Merck Sharp & Dohme LLCInventors: Faben A. Cruz, Danqing Feng, Yan Guo, Jennifer Hanisak, Jennifer L. Hickey, Ahmet Kekec, Bing Li, Michael Man-Chu Lo, Dmitri A. Pissarnitski, Christopher W. Plummer, Stefania Colarusso, Dipannita Kalyani, Quang T. Truong
-
Publication number: 20250154412Abstract: A compound of formula AN a liquid crystal material comprising a compound of formula AN, and high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tuneable filters, tuneable metamaterial structures, and electronic beam steering antennas, e.g., phased array antennas.Type: ApplicationFiled: October 29, 2024Publication date: May 15, 2025Applicant: MERCK PATENT GmbHInventors: Constanze Brocke, Dagmar Klass, Matthias Jost, Amir Hossain Parham
-
Publication number: 20250154173Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.Type: ApplicationFiled: October 31, 2024Publication date: May 15, 2025Applicant: Merck Sharp & Dohme LLCInventors: Barbara Pio, Phieng Siliphaivanh, Abdelghani Abe Achab, Yaroslav Boyko, Yi-Heng Chen, Erin F. DiMauro, Jenny Lorena Rico Duque, Xavier Fradera, Anandan Palani, Meredith M. Rickard, Jing Su, Brandon A. Vara
-
Patent number: 12295998Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.Type: GrantFiled: June 22, 2023Date of Patent: May 13, 2025Assignee: Merck Sharp & Dohme LLCInventors: Julie M. Skinner, Patrick McHugh
-
Patent number: 12297386Abstract: The present invention relates to a compound of formula G as defined in claim 1, to a liquid crystal medium comprising a compound of formula G and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.Type: GrantFiled: October 25, 2021Date of Patent: May 13, 2025Assignee: MERCK PATENT GMBHInventors: Constanze Brocke, Carsten Fritzsch, Dagmar Klass
-
Patent number: 12299619Abstract: An adaptive risk management application retrieves data corresponding to an asset. The asset is a computing device or software application of an enterprise system. The adaptive risk management system identifies a set of vulnerabilities of the asset. For each vulnerability in the set of vulnerabilities, the adaptive risk management application generates a recommendation for mitigating the vulnerability. The adaptive risk management application generates a user interface for the asset. The user interface comprises a list of the recommendations. The adaptive risk management system provides the user interface for display.Type: GrantFiled: June 5, 2020Date of Patent: May 13, 2025Assignee: Merck Sharp & Dohme LLCInventors: Mark Joseph Risoldi, Sethuraman Balasubramanian
-
Patent number: 12297208Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, M, L, Cy, Cz, R1, R2, R3, R4, R2a, Ry, Rz, and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.Type: GrantFiled: May 3, 2023Date of Patent: May 13, 2025Assignee: Merck Sharp & Dohme LLCInventors: Indu Bharathan, Symon Gathiaka, Yongxin Han, Xiaoshen Ma, Ryan D. Otte, David L. Sloman, Thomas H. Graham, Timothy Henderson, Elisabeth Hennessy, Anandan Palani
-
Patent number: 12297537Abstract: Compounds for selectively forming metal-containing films are provided. Methods of forming metal-containing films are also provided. The methods include forming a blocking layer, for example, on a first substrate surface, by a first deposition process and forming the metal-containing film, for example, on a second substrate surface, by a second deposition process.Type: GrantFiled: November 3, 2020Date of Patent: May 13, 2025Assignee: MERCK PATENT GMBHInventors: Charith Nanayakkara, Joby Eldo, Jacob Woodruff, Charles Dezelah, Shawn Sungeun Hong, Ravindra Kanjolia, Daniel Moser, Mark C. Potyen
-
Publication number: 20250145833Abstract: Metal effect pigments, having a surface treatment comprising A) phosphoric acid (H3PO4), B) tetraethyl orthosilicate (TEOS) and C) at least one organic coupling agent to the metal effect pigments, exhibiting excellent humidity resistance performance without any influence on the chroma, luster and color of base metal effect pigments, a process for producing same and their use.Type: ApplicationFiled: February 6, 2023Publication date: May 8, 2025Applicant: MERCK PATENT GmbHInventor: Bangyin LI
-
Patent number: 12291570Abstract: A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.Type: GrantFiled: October 17, 2019Date of Patent: May 6, 2025Assignees: BioLineRx Ltd., Merck Sharp & Dohme Corp.Inventors: Abi Vainstein-Haras, Ella Sorani, Irit Gliko-Kabir, Osnat Bohana-Kashtan, Amnon Peled
-
Patent number: 12291538Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, M, L, Cy, Cz, R1, R2, R3, R4, R2a, Ry, Rz, and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.Type: GrantFiled: May 3, 2023Date of Patent: May 6, 2025Assignee: Merck Sharp & Dohme LLCInventors: Indu Bharathan, Symon Gathiaka, Yongxin Han, Xiaoshen Ma, Ryan D. Otte, David L. Sloman, Thomas H. Graham, Timothy Henderson, Elisabeth Hennessy, Anandan Palani
-
Publication number: 20250136910Abstract: In some embodiments, devices for use as blood-brain barrier models are disclosed. The devices may include either a hydrogel component that surrounds a channel formed between a first opening and a second opening of the hydrogel component, or a hydrogel component that forms a groove. The devices may further include pericytes disposed in the channel or the groove, and endothelial cells may be disposed in the channel or the groove. The hydrogel component may include astrocytes (e.g., printed into the hydrogel component via projection stereolithography). Also disclosed are various methods of making and using these devices.Type: ApplicationFiled: October 16, 2024Publication date: May 1, 2025Applicants: Merck Sharp & Dohme LLC, William Marsh Rice UniversityInventors: Nicole L. Buist, Martha J. Fowler, Yufang He, Anna Kristen Mai, Adam T. Procopio, Madison K. Royse, Omid Veiseh, Jun Xu
-
Publication number: 20250142980Abstract: A layer, sheet or film containing one or more flake-form effect pigments and one or more light scattering centers, methods for its preparation, its use for any type of device collecting solar cell energy, including but not limited to coloring solar cells or solar cell modules, and devices collecting solar cell energy, including but not limited to colored solar cells or colored solar cell modules, comprising such a layer, sheet or film, and methods for their preparation.Type: ApplicationFiled: August 9, 2022Publication date: May 1, 2025Applicant: Merck Patent GmbHInventors: Sebastian BARTH, Laurent DELOUX, Marc HUNGER, Zhen WENG, Claudio BRIGHINA, Jan-Niclas KONZ
-
Publication number: 20250136868Abstract: Liquid-crystalline (LC) media or LC materials and energy saving liquid-crystal displays (LCDs) containing these media, especially gaming displays and AR/VR headsets addressed by an active matrix and in particular to LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type.Type: ApplicationFiled: August 29, 2024Publication date: May 1, 2025Applicant: Merck Patent GmbHInventors: Sven Christian Laut, Hee-Kyu Lee, Jing Wang
-
Patent number: 12286503Abstract: The disclosed subject matter relates compounds of structure (I), and polymers of structure (II) having a polydispersity ranging from 1 to about 1.1, compositions comprising said polymers and a spin casting solvent, the process of forming a pinning layer selectively on metal with said composition and the process of using said pinning layers to affect chemoepitaxy directed self-assembly of an overlying block copolymer, and the subsequent process of pattern transfer of this self-assembled layer into a substrate by etching.Type: GrantFiled: October 18, 2021Date of Patent: April 29, 2025Assignee: Merck Patent GmbHInventors: EunJeong Jeong, Durairaj Baskaran, Jihoon Kim
-
Patent number: 12286449Abstract: Metal complexes including cyclopentadienyl ligands and methods of using such metal complexes to prepare metal-containing films are provided.Type: GrantFiled: March 11, 2022Date of Patent: April 29, 2025Assignee: MERCK PATENT GMBHInventors: Ming Fang, Joby Eldo, Charles Dezelah, Daniel Moser, Ravi Kanjolia
-
Publication number: 20250129183Abstract: The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.Type: ApplicationFiled: September 23, 2024Publication date: April 24, 2025Applicants: Merck Patent GmbH, ABLYNX NVInventors: Francis DESCAMPS, Gerald BESTE, Guy HERMANS, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL
-
Publication number: 20250128216Abstract: A stirring device for stirring a biphasic fluid has a stirring shaft that can be mounted with a mounting end into a stirring drive. The stirring device also has a first paddle that is arranged in a rotationally fixed manner at or near a stirring end of the stirring shaft that is opposite to the mounting end, and further has a second paddle that is arranged in a rotationally fixed manner at the stirring shaft in between the mounting end and the first paddle. The second paddle is mounted with respect to the stirring shaft in such a manner that it can be displaced in an axial direction along the stirring shaft, which allows for a change of an axial distance between the second paddle and the mounting end of the stirring shaft.Type: ApplicationFiled: September 22, 2022Publication date: April 24, 2025Applicant: Merck Patent GmbHInventors: Christian Jede, Kirstin Meiners, Marcel Wedel, Malte Bogdahn
-
Publication number: 20250127938Abstract: The present disclosure relates to new folate-conjugates comprising a 5-methyltetrahydro-folate, a radiometal chelator optionally coordinating a radiometal M, and the albumin binder 5-(p-iodophenyl)pentanoate, and further provides uses of such conjugates and/or pharmaceutical compositions thereof in diagnostic imaging, radionuclide therapy or theragnostic applications.Type: ApplicationFiled: January 30, 2023Publication date: April 24, 2025Applicant: Merck Patent GmbHInventors: Viola GROEHN, Marie-Luise RENZ, Rudolf MOSER, Roger SCHIBLI, Cristina Magdalena MUELLER, Luisa Maria DEBERLE, Anna Elisabeth BECKER, Sara Dorina BUSSLINGER
-
Publication number: 20250127879Abstract: Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.Type: ApplicationFiled: June 7, 2024Publication date: April 24, 2025Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, MEMORIAL SLOAN KETTERING CANCER CENTER, MERCK SHARP & DOHME LLCInventors: Peter PALESE, Adolfo GARCIA-SASTRE, Dmitriy ZAMARIN, Svetlana SADEKOVA, Rachel Allison ALTURA, Uyen PHAN, Brian B. HAINES, Jedd D. WOLCHOK
